A topsy-turvy world

The full implementation of Basel II in Europe next year has caused some banks to question whether they should retain the equity tranches of securitisation transactions on their balance sheets. Some are already selling equity tranches on to hedge funds, but the subprime sell-off in the US could hamper demand for this paper. Duncan Wood reports

risk-0807-26-gif

The world of securitisation is about to be turned upside down. When the new Basel II capital adequacy framework comes into full effect in Europe and parts of Asia and the Middle East at the start of 2008, it will no longer make sense for originating banks to sell the higher-rated paper and retain the riskier notes, as is common under the current regime. Instead, risk levels will determine how much capital banks need to hold, meaning there will be a strong incentive to sell the equity portion and

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here